Discover how abelacimab reduces bleeding risks in AFib patients by effectively lowering free factor XI levels.

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

There is decreased risk for MACE, stroke, and mortality in patients with newly diagnosed atrial fibrillation who regularly use statins.

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, ...

Lower levels of free factor XI and fewer bleeding events seen in patients with atrial fibrillation at moderate-to-high risk for stroke ...

Researchers have found that Factor XI inhibitors, such as abelacimab, reduce bleeding risks in atrial fibrillation patients more effectively than standard anticoagulants.

Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and ...

Atrial fibrillation, or A-fib, is an irregular heart rhythm that increases a person's risk of stroke, heart failure and even ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

Use of smokeless tobacco, cigars, and pipes increased the risk for coronary heart disease and heart attacks, according to a ...

Atrial fibrillation (AF) is the most common cardiac arrhythmia and predisposes patients to stroke and systemic embolism. Vitamin K antagonists have been the only available oral anticoagulants for ...